Biosimilar Medication Formulary Updates
Sep. 2025Pharmacy Updates
Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab products
In ongoing efforts to improve the value and affordability of health care benefits for our members, UPMC Health Plan has implemented biosimilar medication formulary updates for denosumab, eculizumab, and ustekinumab products. Effective dates for these changes are as follows.
- UPMC for Life (Medicare/Special Needs Plan):
- Part D formularies effective Sept. 1, 2025
- Part B policies effective Sept. 10, 2025
- UPMC Health Plan (Commercial/Exchange) and UPMC for Kids (CHIP): Formularies effective Oct. 1, 2025
- UPMC for You and UPMC CHC: Effective Oct. 1, 2025
For full details on these changes, please refer to pages 18-19 in the September 2025 edition of Provider Partner Update.
Recent Announcements
October 2025 UPMC for You and UPMC Community HealthChoices formulary update
Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.Oct. 2025Pharmacy Updates
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates
HelpScript service helps patients enroll in manufacturer copay assistance programs
End-to-end provider support helps ensure a smooth submission processOct. 2025Important Notices